Aniline

CASRN 62-53-3

  • IRIS Summary (PDF) (19 pp, 139 K)
  • Status: Aniline is not being reassessed by IRIS at this time.

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (19 pp, 139 K)
Not assessed under the IRIS Program.

Reference Concentration for Inhalation Exposure (RfC) (PDF) (19 pp, 139 K) last updated: 11/01/1990

RfC (mg/m3) System Basis PoD Composite UF Confidence
1 x10-3 Immune Lack of toxicity NOAEL (HEC): 3.4
mg/m3
3000 Low

Cancer Assessment


Weight of Evidence for Cancer (PDF) (19 pp, 139 K) last updated: 09/07/1988

WOE Characterization Framework for WOE Characterization
B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Induction of tumors of the spleen and the body cavity in two strains of rat, and some supporting genetic toxicological evidence.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (19 pp, 139 K)

Oral Slope Factor: 5.7 x10 -3 per mg/kg-day
Drinking Water Unit Risk: 1.6 x10 -7 per µg/L
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Immune
Tumor type(s): Spleen, combined fibrosarcoma, stromal sarcoma, capsular sarcoma and hemangiosarcoma (CIIT, 1982)


Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (19 pp, 139 K)

Not Assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.